Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervica...Подробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

The OncoAlert Colloquium Day 3 Breast CancerПодробнее

The OncoAlert Colloquium Day 3 Breast CancerПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Targeting the PI3K Pathway in the Therapy of Breast Cancer - by Jose Baselga, MD, PhDПодробнее

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, TargetsПодробнее

Phase III KATHERINE Clinical TrialПодробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

What's New and on the Horizon for Metastatic Breast Cancer?Подробнее

Advances in HER2-positive and HER2-low Breast CancerПодробнее